Elaine M. Sloand, MD; Phillip Scheinberg, MD; Jaroslaw Maciejewski, MD; Neal S. Young, MD
Sloand EM, Scheinberg P, Maciejewski J, Young NS. Brief Communication: Successful Treatment of Pure Red-Cell Aplasia with an Anti–Interleukin-2 Receptor Antibody (Daclizumab). Ann Intern Med. 2006;144:181-185. doi: 10.7326/0003-4819-144-3-200602070-00006
Download citation file:
Published: Ann Intern Med. 2006;144(3):181-185.
Pure red-cell aplasia (PRCA) seems to have an autoimmune pathophysiology. Currently available treatments are relatively toxic. Daclizumab is a genetically engineered human IgG1 that blocks the interleukin-2 receptor necessary for clonal expansion of activated T cells.
Fifteen patients with PRCA were treated with daclizumab. Forty percent achieved normal hemoglobin levels within 18 months of starting therapy. The drug produced little toxicity other than minor skin rash.
Daclizumab may provide a nontoxic alternative for treating a severe, relatively refractory cause of anemia.
This is a small, unblinded study.
Fifteen patients with pure red-cell aplasia were treated with daclizumab, 1 mg/kg of body weight, as described in the Methods section. Reticulocyte count, hemoglobin level, and transfusion history are seen for each patient. To convert hemoglobin values from g/dL to g/L, multiply value by 10.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Hematology/Oncology, Red Cell Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only